Cyclo(RGDyC) TFA is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) TFA can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer.
References:
[1]. Lu Y, et al. Aqueous synthesized near-infrared-emitting quantum dots for RGD-based in vivo active tumour targeting. Nanotechnology. 2013 Apr 5;24(13):135101.
[2]. Tang M, et al. Photostable and Biocompatible Fluorescent Silicon Nanoparticles-Based Theranostic Probes for Simultaneous Imaging and Treatment of Ocular Neovascularization. Anal Chem. 2018 Jul 3;90(13):8188-8195.
















